[HTML][HTML] Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind …
J Tabernero, RR Hozak, T Yoshino, AL Cohn… - Annals of …, 2018 - Elsevier
Abstract Background The phase III RAISE trial (NCT01183780) demonstrated that the
vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody …
vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody …
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line …
J Tabernero, T Yoshino, AL Cohn… - The Lancet …, 2015 - thelancet.com
Background Angiogenesis is an important therapeutic target in colorectal carcinoma.
Ramucirumab is a human IgG-1 monoclonal antibody that targets the extracellular domain of …
Ramucirumab is a human IgG-1 monoclonal antibody that targets the extracellular domain of …
An open‐label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX‐6 as first‐line therapy for metastatic colorectal cancer
R Garcia‐Carbonero, F Rivera, J Maurel… - The …, 2014 - academic.oup.com
Abstract Author Summary Background. Vascular endothelial growth factor (VEGF) and VEGF
receptor 2 (VEGFR‐2) are believed to mediate angiogenesis in colorectal cancer (CRC) …
receptor 2 (VEGFR‐2) are believed to mediate angiogenesis in colorectal cancer (CRC) …
Safety and pharmacokinetics of second-line ramucirumab plus FOLFIRI in Japanese patients with metastatic colorectal carcinoma
T Yoshino, K Yamazaki, M Gotoh… - Anticancer …, 2015 - ar.iiarjournals.org
Background: This phase Ib study evaluated the pharmacokinetic profile and safety of
ramucirumab, a recombinant human IgG1 neutralizing monoclonal antibody specific for …
ramucirumab, a recombinant human IgG1 neutralizing monoclonal antibody specific for …
RAISE: A randomized, double-blind, multicenter phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab (RAM) or placebo (PBO) in …
512 Background: Angiogenesis is an important therapeutic target in CRC; VEGF plays a key
role in angiogenesis. RAM is a human IgG1 monoclonal antibody that targets the …
role in angiogenesis. RAM is a human IgG1 monoclonal antibody that targets the …
[HTML][HTML] Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial
T Yoshino, R Obermannová, G Bodoky… - European journal of …, 2017 - Elsevier
Abstract Background The RAISE phase III clinical trial demonstrated that
ramucirumab+(folinic acid plus 5-fluorouracil plus irinotecan) FOLFIRI significantly improved …
ramucirumab+(folinic acid plus 5-fluorouracil plus irinotecan) FOLFIRI significantly improved …
Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
H Verdaguer, J Tabernero… - Therapeutic advances in …, 2016 - journals.sagepub.com
Colorectal cancer is the third most frequent cancer worldwide. Overall survival rates have
improved greatly over the last few years due, at least in part, to the addition of targeted …
improved greatly over the last few years due, at least in part, to the addition of targeted …
[HTML][HTML] Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic …
T Yoshino, DC Portnoy, R Obermannova, G Bodoky… - Annals of …, 2019 - Elsevier
Background Second-line treatment with ramucirumab+ FOLFIRI improved overall survival
(OS) versus placebo+ FOLFIRI for patients with metastatic colorectal carcinoma …
(OS) versus placebo+ FOLFIRI for patients with metastatic colorectal carcinoma …
Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature
M Pohl, N Werner, J Munding… - Zeitschrift für …, 2011 - thieme-connect.com
Zusammenfassung Einleitung: Das kolorektale Karzinom (KRK) ist die zweithäufigste
krebsbedingte Todesursache in der westlichen Industriewelt. Der monoklonale anti-VEGF …
krebsbedingte Todesursache in der westlichen Industriewelt. Der monoklonale anti-VEGF …
[HTML][HTML] Randomized phase II study of modified FOLFOX-6 in combination with ramucirumab or icrucumab as second-line therapy in patients with metastatic colorectal …
M Moore, S Gill, T Asmis, S Berry, R Burkes, K Zbuk… - Annals of oncology, 2016 - Elsevier
In this phase II study in patients with metastatic colorectal cancer following disease
progression on first-line irinotecan-based therapy, combining ramucirumab or icrucumab …
progression on first-line irinotecan-based therapy, combining ramucirumab or icrucumab …